Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

2014302 citationsReviewbronze Open Access

Authors

Tofacitinib demonstrated consistent safety and persistent efficacy over 48 months in patients with RA.

Good health and well-being

Published in: The Journal of Rheumatology

Volume 41, Issue 5, pp. 837-852

Field-Weighted Citation Impact: 25.25